Phase 1 of the study will open first with a (Bayesian optimal interval BOIN) dose finding design. The starting dose of tomivosertib is 100mgdaily (doses 24 ± 2 hours apart), PO, self-administered with meals. The dose finding follows a BOIN design, with the 100mg BID dose level with a meal being the highest dose. There is one dose level below (dose level -1 = 100mg QD without a meal) that will be given if the de-escalation condition is met during dose finding. Upon completion of the phase 1 dose finding portion of the study, the recommended starting dose of tomivosertib for the subsequent combination with the other agents will be determined, as described in Section 4.3 and Section 8.0.
Tomivosertib will be dosed continuously on days 1-28 of each 28-day cycle at the dose level assigned for that cohort.

开始日期2023-09-29

申办/合作机构

Northwestern University

[+2]

NCT04632381 / Completed临床1期

A Phase 1b, Randomized, Double-Blind, Placebo-Controlled, Dose Escalation Trial of Intravenous Zotatifin in Adults With Mild or Moderate Coronavirus Disease 2019 (COVID-19)

To evaluate the safety and tolerability, the antiviral activity, and plasma pharmacokinetics (PK) of zotatifin administered intravenously (IV) to adults with mild or moderate COVID-19.

开始日期2021-07-01

申办/合作机构

eFFECTOR Therapeutics Operations, Inc.

[+1]

NCT04622007 / Active, not recruiting临床2期

A Randomized, Double-Blind, Placebo-Controlled Trial of Tomivosertib in Combination With Anti-PD-(L)1 Therapy in Subjects With NSCLC as First Line Therapy or When Progressing on Single-Agent First-Line Anti PD (L)1 Therapy

Tomivosertib combined with pembrolizumab in Subjects with PD-L1 positive NSCLC

开始日期2021-06-02

申办/合作机构

eFFECTOR Therapeutics Operations, Inc.

[+2]

100 项与 eFFECTOR Therapeutics, Inc. 相关的临床结果

登录后查看更多信息

0 项与 eFFECTOR Therapeutics, Inc. 相关的专利（医药）

登录后查看更多信息

项与 eFFECTOR Therapeutics, Inc. 相关的文献（医药）

2024-05-02·Cancer Research

Abstract PO5-05-03: Phase 1/2 Dose Expansion Study Evaluating First-In-Class eIF4A Inhibitor Zotatifin in Patients with ER+ Metastatic Breast Cancer

作者: Sperry, Samuel ; Densel, Mark ; Chiang, Gary ; Warner, Douglas ; Fulgar, Georgina ; Meric-Bernstam, Funda ; Rosen, Ezra Y. ; Berz, David ; Caswell-Jin, Jennifer ; Sharma, Manish

AbstractBackgroundZotatifin (eFT226) is a first-in-class, potent and sequence selective inhibitor of RNA helicase eIF4A that promotes a stable mRNA:eIF4A:drug ternary complex at specific polypurine motifs present within the 5’-UTR of select transcripts, thereby blocking production of the encoded proteins. In preclinical models zotatifin treatment simultaneously down-regulated translation of numerous oncogenes including CDK4, ERα, ERBB2, KRAS, and CCND1. Previous clinical research has demonstrated the activity of zotatifin in combination with other agents in ER+ metastatic breast cancer (MBC).MethodsPart 1 is a 3+3 dose escalation portion of the protocol followed by Part 2 as a Simon’s two-stage design in patients with ER+ MBC enrolled at the recommended phase 2 dose (RP2D) of zotatifin (0.07 mg/kg IV two weeks on/one week off) in combination with fulvestrant (ful) and abemaciclib (abema) (Z+F+A). Part 1a and Part 1b are 3+3 dose escalation portions evaluating zotatifin in combination with ful (Z+F) at QW IV and Q2W IV dosing schedules, respectively. Key eligibility criteria included at least one line of therapy for advanced/metastatic disease, progression on hormone therapy, and in addition, the Z+F cohorts required prior CDK 4/6 inhibitor (CDKi). Primary endpoint of Part 1a/1b was determination of RP2D and primary endpoint of part 2 was objective response rate (ORR) per RECIST v1.1. Additional endpoints included safety, progression-free survival (PFS) and other efficacy analyses, and characterization of pharmacodynamic (PD) markers and pharmacokinetics.ResultsAs of a data cut-off of July 6, 2023, 20 pts were enrolled in the Z+F+A cohort and had a median of four prior metastatic lines of therapy. In 19 evaluable pts in Z+F+A cohort, there were four confirmed partial responses (PR), one unconfirmed PR, and 10 pts with best overall response (OR) of stable disease (SD). All pts with PR/unconfirmed PR received prior CDKI, ful, and chemotherapy for MBC. Confirmed PRs were observed in patients with and without mutations in ESR1 and PIK3CA. mPFS, while not yet mature, exceeds 20 weeks. In Z+F+A the most common adverse events (AEs) were diarrhea (80%, all grades (Gr)) and nausea (75%, all Gr 1/2) and the most common Gr 3/4 AE was diarrhea (15%). In Z+F cohorts of 0.07 mg/kg QW (n=3), 0.1 mg/kg Q2W (n=3), and 0.14 Q2W (n= 2) there were no dose-limiting toxicities or Gr 5 adverse events (AEs). There was one confirmed PR and one SD in 0.1 and 0.14 mg/kg Q2W cohorts, respectively, and no PR or SD in the 0.07 mg/kg QW cohort. In Z+F+A, 9 pts had paired pre- and on-treatment ctDNA analyzed by Guardant assay. Of the remaining 11 pts, 4 came off study prior to scheduled collection of the on-treatment sample and 5 had unavailable samples. Of the 9 patients with paired samples, 8 had ctDNA decreases of >50%, all of whom had SD or PR. In the Z+F Q2W cohort, 2 of 3 patients had ctDNA decreases >50%, one of whom had a PR. Reduction below the limit of detection was seen for mutant alleles in ESR1, PIK3CA and other genes with potential to confer resistance to endocrine therapy.ConclusionZ+F+A showed encouraging efficacy in heavily pretreated ER+ MBC patients, with results that compare favorably to other treatment options available after progression on CDKi plus endocrine treatment. Efficacy was seen independent of ESR1 or PIK3CA mutations, suggesting the potential to treat a broad, unrestricted patient population. Initial results with Z+F Q2W dosing are encouraging and support continued dose escalation of this regimen.Citation Format: Ezra Y. Rosen, Manish Sharma, David Berz, Jennifer Caswell-Jin, Georgina Fulgar, Mark Densel, Gary Chiang, Samuel Sperry, Douglas Warner, Funda Meric-Bernstam. Phase 1/2 Dose Expansion Study Evaluating First-In-Class eIF4A Inhibitor Zotatifin in Patients with ER+ Metastatic Breast Cancer [abstract]. In: Proceedings of the 2023 San Antonio Breast Cancer Symposium; 2023 Dec 5-9; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2024;84(9 Suppl):Abstract nr PO5-05-03.

2021-12-01·Cancer Chemotherapy and Pharmacology4区 · 医学

Single- and multiple-dose pharmacokinetics, potential for CYP3A inhibition, and food effect in patients with cancer and healthy subjects receiving ipatasertib

4区 · 医学

Article

作者: Tabernero, Josep ; Meng, Raymond ; Sane, Rucha ; Liederer, Bianca ; Budha, Nageshwar ; Huang, Jian ; Cervantes, Andres ; Deng, Yuzhong ; Malhi, Vikram ; Musib, Luna ; Patel, Premal

PURPOSETo examine the single- and multiple-dose pharmacokinetics (PK), CYP3A inhibition potential of ipatasertib, and effect of food on PK of ipatasertib in patients with refractory solid tumors and a dedicated food effect assessment in healthy subjects.METHODSThe Phase I dose-escalation study enrolled patients with solid tumors in a standard 3 + 3 design with a 1 week washout after the first dose, followed by once-daily dosing on a 3-week-on/1-week-off schedule. In the expansion cohort, the effect of ipatasertib on CYP3A substrate (midazolam) was assessed by examining the change in midazolam exposure when dosed in the absence and presence of steady-state ipatasertib at 600 mg. The effect of food on ipatasertib PK was studied with ipatasertib administered in fed or fasted state (6 patients from Phase I patient study and 18 healthy subjects from the dedicated food effect study).RESULTSIpatasertib was generally well tolerated at doses up to 600 mg given daily for 21 days. Ipatasertib showed rapid absorption (t_max, 0.5-3 h), was dose-proportional over a range of 200-800 mg, had a median half-life (range) of 45.0 h (27.8-66.9 h), and had approximately two-fold accumulation following once-daily dosing. Midazolam exposure (AUC_0-∞) increased by 2.2-fold in the presence of ipatasertib. PK was comparable in subjects administered ipatasertib in a fed or fasted state.CONCLUSIONIpatasertib exhibited rapid absorption and was dose-proportional over a broad dose range. Ipatasertib appeared to be a moderate CYP3A inhibitor when administered at 600 mg and could be administered with or without food in clinical studies.TRAIL REGISTRATIONNCT01090960 (registered March 23, 2010); NCT02536391 (registered August 31, 2015).

2021-01-01·Molecular Cancer Therapeutics2区 · 医学

Targeting Oncogene mRNA Translation in B-Cell Malignancies with eFT226, a Potent and Selective Inhibitor of eIF4A

2区 · 医学

Article

作者: Nilewski, Christian ; Thompson, Peggy A. ; Parra, Ana ; Reich, Siegfried H. ; Fish, Sarah ; Sperry, Samuel ; Staunton, Jocelyn ; Tran, Chinh ; Clarine, Jeff ; Young, Nathan P. ; Eam, Boreth ; Chen, Joan ; Chiang, Gary G. ; Wegerski, Christopher J. ; Michels, Theodore ; Barrera, Maria ; Howard, Haleigh ; Ernst, Justin T. ; Gerson-Gurwitz, Adina ; Nevarez, Andres ; Packard, Garrick K. ; Sprengeler, Paul A. ; Xiang, Alan ; Sung, Eric ; Webster, Kevin R.

AbstractThe PI3K/AKT/mTOR pathway is often activated in lymphoma through alterations in PI3K, PTEN, and B-cell receptor signaling, leading to dysregulation of eIF4A (through its regulators, eIF4B, eIF4G, and PDCD4) and the eIF4F complex. Activation of eIF4F has a direct role in tumorigenesis due to increased synthesis of oncogenes that are dependent on enhanced eIF4A RNA helicase activity for translation. eFT226, which inhibits translation of specific mRNAs by promoting eIF4A1 binding to 5′-untranslated regions (UTR) containing polypurine and/or G-quadruplex recognition motifs, shows potent antiproliferative activity and significant in vivo efficacy against a panel of diffuse large B-cell lymphoma (DLBCL), and Burkitt lymphoma models with ≤1 mg/kg/week intravenous administration. Evaluation of predictive markers of sensitivity or resistance has shown that activation of eIF4A, mediated by mTOR signaling, correlated with eFT226 sensitivity in in vivo xenograft models. Mutation of PTEN is associated with reduced apoptosis in vitro and diminished efficacy in vivo in response to eFT226. In models evaluated with PTEN loss, AKT was stimulated without a corresponding increase in mTOR activation. AKT activation leads to the degradation of PDCD4, which can alter eIF4F complex formation. The association of eFT226 activity with PTEN/PI3K/mTOR pathway regulation of mRNA translation provides a means to identify patient subsets during clinical development.

项与 eFFECTOR Therapeutics, Inc. 相关的新闻（医药）

2024-06-27

·药渡

【药企裁员风波渐退】六月汇总

来源：药渡撰文：五月编辑：哦呼六月药企裁员潮渐退，相较于之前数月的密集发布，本月约有7家药企公布了减员计划，如下表所示。 6月药企裁员名单 6月24日近期，G1 Therapeutics公布了其用于评估化疗前给药的曲拉西利（吉西他滨和卡铂；GCb）在转移性TNBC患者中疗效的3期PRESERVE 2试验结果，研究结果显示在风险比（HR）为0.91（p=0.884）的ITT人群（n=187）中未显示出具有统计学意义的治疗效果（图1）。曲拉西利加GCb组的中位总生存期（OS）为17.4个月，而对照组为17.8个月。在两个PD-L1亚组（阳性和阴性）中，中位OS在数值上都有利于曲拉西利组，尽管两者都没有达到统计学意义。不同地区和接受不同类型后续治疗的患者观察到不同的效果;这些发现将进一步评估。在试验中观察到的含GCb的曲拉西利的安全性与先前的研究一致，并且没有发现新的安全信号。与其他曲拉西利研究一致，观察到骨髓保护的证据，包括严重中性粒细胞减少的发生率降低，在接受曲拉西利治疗的患者中，有8%的患者发生严重中性粒细胞减少症，而对照组为29%[1]。图1. G1 Therapeutics公布3 期 PRESERVE 2 试验结果与此同时，G1还宣布将“停止预期雇用员工”。为了坚持到2025年下半年实现盈利的雄心壮志，这家生物技术公司还将“在现有商业组织之外有针对性地裁员，以精简公司”。该新闻稿没有提供关于有多少员工可能受到影响的线索。 6月24日肿瘤生物技术公司eFFECTOR Therapeutics宣布已经开始裁员，包括eFFECTOR首席执行官Stephen Worland博士、首席财务官Michael Byrnes、首席医疗官Douglas Warner医学博士，他们都在上周末停止了他们的职位[2]。根据美国证券交易委员会的文件，该公司预计到6月30日将花费约60万美元用于与裁员相关的一次性费用和现金支出。与此同时，董事会已任命Craig Jalbert担任eFFECTOR的首席执行官、总裁、财务主管、秘书和唯一董事会成员。Jalbert是会计师事务所 Verdolino & Lowey， P.C. 的负责人，拥有三十多年帮助公司倒闭的经验。接下来的部分步骤包括为eFFECTOR的开发计划寻找战略替代方案。这家生物技术公司的主要资产是zotatifin，这是一种选择性的eIF4A抑制剂，正在几项针对实体瘤的中期试验中进行测试。今年4月，eFFECTOR的另一家全资资产tomivosertib在一项针对非小细胞肺癌（NSCLC）患者的2b期试验中未能改善无进展生存期。根据初步分析中提供的所有数据，该公司表示，在一线NSCLC中继续开发该资产没有明显的前进道路。 eFFECTOR还与大型制药公司辉瑞合作开发了一种名为eIF4Ei的临床前资产，该资产也旨在治疗实体瘤。2019年，辉瑞公司在一项独家许可协议中预先支付了1500万美元，与eFFECTOR合作开发真核起始因子4E（eIF4E）的小分子抑制剂，这笔价值5.07亿美元的交易被搁置。 6月21日上个月宣布削减高达25%的劳动力成本Ginkgo Bioworks这个月继续裁员，宣布将裁员158人[3]。 Ginkgo的一位发言人告诉该媒体，这家总部位于波士顿的公司将在下周披露更多的裁员，但没有透露裁员人数。 Ginkgo于2014年成功从硅谷Y Combinator孵化，并拿到风险投资。2021年，Ginkgo通过SPAC（特殊目的收购公司）成功上市，是一家致力于成为开发细胞编程技术的生物合成领域的横向“平台型”企业。 6月20日 Cara Therapeutics在6月14日提交给美国证券交易委员会的文件中披露，该公司将在本月底前裁员70%。就在两天前，Cara Therapeutics宣布了KOURAGE-1研究的剂量探索A部分的结果，该研究评估了口服地非利福林治疗成年感觉异常（NP）患者中度至重度瘙痒的疗效和安全性。与安慰剂相比，口服地非利福林在任何剂量下均未显示出有意义的临床益处，导致公司决定终止其临床项目（图2）[4]。图2. Cara Therapeutics公布KOURAGE-1研究结果截至2024年3月31日，公司拥有约7000万美元的现金、现金等价物和有价证券。在最新的裁员之前，Cara在1月份宣布裁员高达50%。根据其LinkedIn个人资料，总部位于康涅狄格州斯坦福德的公司拥有51-200名员工。 6月13日总部位于英国牛津的Barinthus Biotherapeutics在周三的一份新闻稿中表示，遵循“管道优先权”原则，Barinthus Biotherapeutics将裁员约25%，并估计将现金跑道延长至2026年第二季度。 Barinthus正在将其资源投入到慢性乙型肝炎和乳糜泻的项目上，降低前列腺癌候选者的优先级（图3）。 Barinthus最近在欧洲肝脏研究协会（EASL）大会上公布了其乙型肝炎候选药物VTP-300正在进行的两项II期试验的积极中期数据：VTP-300具有显着降低和维持乙型肝炎表面抗原（HBsAg）水平的潜力，并在慢性乙型肝炎（CHB）患者中达到无法检测到的HBsAg水平。 Barinthus还指出，其主要候选药物VTP-1000的乳糜泻药物的临床前发现“令人鼓舞”，这是将该资产与VTP-300一起优先考虑的原因。图3. Barinthus Biotherapeutics的研发管线据LinkedIn称，Barinthus正在开发新型T细胞免疫治疗候选药物，拥有51至200名员工。 VTP-1000旨在通过诱导麸质特异性T调节细胞和减少麸质特异性T效应细胞反应来平衡免疫反应。在疾病模型的临床前研究证明“作用方式和疾病改善”之后，Barinthus表示，它正准备在第三季度将VTP-1000带入临床。 6月12日根据WARN通知，安捷伦科技公司将于8月9日起裁员近200名加州员工，裁员包括CDMO圣克拉拉总部的156名员工，圣巴巴拉县的7名员工，圣地亚哥县的17名员工和佛森的4名员工。公司发言人Sarah Litton告诉SFGATE，裁员是“跨业务和地区”裁员3%的一部分，安捷伦的目标是“适应市场复苏的步伐”。安捷伦报告称，今年第一季度的收入与去年同期相比下降了5.6%。在此之前，该公司在2023年底报告了加州裁员，并于2024年1月生效。 6月6日根据Fierce Pharma报道的一个警告通知，BMS将在2024年剩余的几个月里在新泽西州劳伦斯维尔裁员863人。这家制药巨头在4月份宣布，它将实施一项全面的“战略生产力计划”，以期到2025年节省约15亿美元的成本，包括到今年年底减少约2200个工作岗位。新泽西州裁员的新披露是在3月份 WARN 通知劳伦斯维尔裁员75人之后发布的。据BMS 2024Q1财报，其Q1营收增长了5%，至119亿美元，超过此前115亿美元的预期，但是其Opdivo（纳武利尤单抗）的销售额下降6%，为21亿美元。低于2023年同期22亿美元的收入。此外，CAR-T疗法Abecma受”持续竞争”和“不利的定价压力”影响，销售额也下降了44%，仅为8200万美元，而去年为1.47亿美元（图4）[5]。图4. 2024Q1 BMS主要肿瘤产品销售额参考文献 1. G1 THERAPEUTICS PROVIDES UPDATE ON PHASE 3 PRESERVE 2 TRIAL IN PATIENTS RECEIVING TRILACICLIB PRIOR TO FIRST LINE CHEMOTHERAPY IN METASTATIC TRIPLE NEGATIVE BREAST CANCER (MTNBC) 2. The end of eFFECTOR Therapeutics: Oncology biotech winds down after mid-stage fail 3. Biopharma Layoff Tracker 2024:Ginkgo, Cara, Barinthus and MoreCut Staff 4. Cara Therapeutics Announces Outcome of Part A of KOURAGE-1 Study Evaluating Oral Difelikefalin in Notalgia Paresthetica 5. Bristol Myers Squibb Q1 2024 Results April 25, 2024 编者按：在医药竞争的浪潮中，现金流稳定是药企稳健前行的关键。通过缩减人员、精简产品线等方式来缓解资金压力虽能短期内止血，却难以根治深层次的资金问题。药企需要更全面、更长远的策略来确保资金链的健康与持续。专栏作者五月药物化学硕博，国外博士后，现从事药物研发工作，热爱医药行业，愿与各位同行互相学习、进步，共同见证创新药的发展。 *声明：本文仅是介绍医药疾病领域研究进展或简述研究概况或分享医药相关讯息，并非也不会进行治疗或诊断方案推荐，也不对相关投资构成任何建议。内容如有疏漏，欢迎沟通指出！点击下方“药渡“，关注更多精彩内容股价飙升39%：RNAi疗法时代来临武田制药药物交易风云：近年数据透视其战略布局新动向 100%预防艾滋！吉利德科学创新药物Lenacapavir 3期临床结果喜人点击下方关注，聚焦医药创新一手资讯

高管变更临床3期临床结果

2024-06-24

·FierceBiotech

The end of eFFECTOR Therapeutics: Oncology biotech winds down after midstage fail

Part of the next steps include looking for strategic alternatives for eFFECTOR’s development programs. It’s the end of an era—eFFECTOR Therapeutics’ era to be exact. The oncology biotech has laid off staff as it plans to wind down, according to a June 24 company release. This includes eFFECTOR CEO Stephen Worland, Ph.D.; Chief Financial Officer Michael Byrnes; and Chief Medical Officer Douglas Warner, M.D., who all stopped serving in their positions at the end of last week. The company expects to spend about $600,000 by June 30 in one-time charges and cash expenditures tied to the workforce reduction, according to Securities and Exchange Commission documents. In the meantime, the board of directors has tapped Craig Jalbert to lead as eFFECTOR’s CEO, president, treasurer, secretary and sole board member. Jalbert is a principal from the accounting firm Verdolino & Lowey, P.C., and has more than three decades of experience helping companies wind down. Part of the next steps include looking for strategic alternatives for eFFECTOR’s development programs. The biotech’s lead asset is zotatifin, a selective eIF4A inhibitor being tested out in several mid-stage trials for solid tumors. In April, the company's other wholly-owned asset, tomivosertib, failed to improve progression-free survival in a phase 2b trial of patients with non-small cell lung cancer (NSCLC). Based on all the data available in the primary analysis, the company said it didn't see an obvious path forward for continuing development of the asset in frontline NSCLC. eFFECTOR also had a partnership with Big Pharma Pfizer for a preclinical asset dubbed eIF4Ei, which is also designed to tackle solid tumors. The $507 million biobucks deal was struck back in 2019 when Pfizer paid out $15 million up front in an exclusive licensing agreement to develop small-molecule inhibitors of eukaryotic initiation factor 4E (eIF4E) with eFFECTOR. The biotech was founded in 2012 based on research from the University of California, San Francisco labs of Davide Ruggero, Ph.D., and Kevan Shokat, Ph.D. eFFECTOR plans to ask to be delisted from the Nasdaq. Since announcing the planned shuttering, the biotech’s stock plummeted 77% from $1.17 per share at market close Friday to 29 cents this morning at opening.

临床2期引进/卖出高管变更临床1期

2024-06-24

·BioSpace

eFFECTOR Therapeutics Announces it will Wind Down Operations as it Seeks Strategic Alternatives and Expects to be Delisted from Nasdaq

SOLANA BEACH, Calif. and REDWOOD CITY, Calif., June 24, 2024 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR) today announced that the Company has terminated its employees and will wind down it operations, including seeking potential strategic alternatives for the Company’s development programs. This decision was made at a special meeting of the board of directors. Further, as previously disclosed, the Company’s securities do not presently meet the continued listing requirements of the Nasdaq Stock Market and its securities would be subject to delisting if the Company fails to regain compliance during the required compliance period. The Company plans to voluntarily request a delisting of its securities and expects its securities to be delisted in the near term. The board of directors appointed Craig R. Jalbert, age 62, as the Company’s CEO, President, Treasurer and Secretary, and sole member of the board. Mr. Jalbert has served as a principal of the Foxborough, Massachusetts accounting firm of Verdolino & Lowey, P.C. since 1987. For over 30 years he has focused his practice in distressed businesses and has served, and continues to serve, in the capacities of officer and director for numerous firms in their wind-down phases. Forward-Looking Statements eFFECTOR cautions you that statements contained in this press release regarding matters that are not historical facts are forward-looking statements. The forward-looking statements are based on our current beliefs and expectations and include, but are not limited to, plans to wind down our operations, delist from Nasdaq and seek strategic alternatives. Actual results may differ from those set forth in this press release due to the risks and uncertainties inherent in our business, including, without limitation: our lender declaring a default under our loan and security agreement and accelerating all of our repayment obligations, which we expect will exceed our current available capital, and taking control of our pledged assets, which right to repayment would be senior to the rights of the holders of our common stock to receive any proceeds from any liquidation of the company; the timing, progress and results of our planned wind down and evaluation of strategic alternatives, including whether or not the evaluation of alternatives results in any transaction or additional value beyond our debt obligations; and other risks described in our prior filings with the Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and we undertake no obligation to update such statements to reflect events that occur or circumstances that exist after the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, which is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Contacts: Verdolino & Lowey, P.C. 124 Washington Street, Suite 101 Foxboro, MA. 02035 Phone - 508-543-1720 Effector@vlpc.com

高管变更

100 项与 eFFECTOR Therapeutics, Inc. 相关的药物交易

登录后查看更多信息

100 项与 eFFECTOR Therapeutics, Inc. 相关的转化医学

登录后查看更多信息

组织架构

使用我们的机构树数据加速您的研究。

或

查看完整样例数据

管线布局

2024年12月23日管线快照

管线布局中药物为当前组织机构及其子机构作为药物机构进行统计，早期临床1期并入临床1期，临床1/2期并入临床2期，临床2/3期并入临床3期

临床前

临床1期

临床2期

其他

登录后查看更多信息

当前项目

药物(靶点)	适应症	全球最高研发状态

Zotatifin ( eIF4A )	ER阳性乳腺癌更多	临床2期
阿贝西利 ( CDK4 x CDK6 )	卵巢癌更多	临床2期
Tomivosertib ( MNK1 x MNK2 )	PD-L1阳性肺癌更多	临床2期
elF4E (eFFECTOR Therapeutics)	实体瘤更多	临床1期
eIF4Ei ( EIF4E )	实体瘤更多	临床前